Aurélie Brunet
About
Aurélie Brunet is a scholar working on Surgery, Economics and Econometrics and Immunology.
According to data from OpenAlex, Aurélie Brunet has authored 22 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 6 papers in Economics and Econometrics and 6 papers in Immunology. Recurrent topics in Aurélie Brunet's work include Lipoproteins and Cardiovascular Health (13 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Systemic Lupus Erythematosus Research (4 papers). Aurélie Brunet is often cited by papers focused on Lipoproteins and Cardiovascular Health (13 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Systemic Lupus Erythematosus Research (4 papers). Aurélie Brunet collaborates with scholars based in France, United States and United Kingdom. Aurélie Brunet's co-authors include William J. Sasiela, Franck Poitiers, Corinne Hanotin, A. Thomas DiCioccio, David Fabre, Fabrice Hurbin, Catherine Lunven, Christopher P. Cannon, Nassim Djebli and Virginie Loizeau and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Atherosclerosis.
In The Last Decade
Aurélie Brunet
22 papers receiving 257 citations
Peers
Aurélie Brunet
Jennie Chang United States
Bas Peters Netherlands
Julius L. Katzmann Germany
Donald Moshen Tanyanyiwa South Africa
Sanae Kourimate France
Francine Petrides Australia
Kévin Chemello France
Joseph Rubino United States
Ian Mongrain Canada
Jared Spitz United States
Citations per year, relative to Aurélie Brunet Aurélie Brunet (= 1×)
peers
Jennie Chang
Countries citing papers authored by Aurélie Brunet
Since
Specialization
Citations
This map shows the geographic impact of Aurélie Brunet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Brunet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Brunet more than expected).
Fields of papers citing papers by Aurélie Brunet
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Aurélie Brunet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Brunet. The network helps show where Aurélie Brunet may publish in the future.
Co-authorship network of co-authors of Aurélie Brunet
This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Brunet. A scholar is included among the top collaborators of Aurélie Brunet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Brunet. Aurélie Brunet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Djebli, Nassim, et al.. (2022). Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies. European Journal of Drug Metabolism and Pharmacokinetics. 47(6). 789–802.
2.
Brunet, Aurélie, Yohan N’Guyen, A. Lefèbvre, et al.. (2020). Obesity and Preoperative Anaemia as Independent Risk Factors for Sternal Wound Infection After Coronary Artery Bypass Graft Surgery with Pedicled (Non-Skeletonized) Internal Mammary Arteries: The Role of Thoracic Wall Ischemia?. SHILAP Revista de lepidopterología.
3.
Brunet, Aurélie, Yohan N’Guyen, A. Lefèbvre, et al.. (2020). <p>Obesity and Preoperative Anaemia as Independent Risk Factors for Sternal Wound Infection After Coronary Artery Bypass Graft Surgery with Pedicled (Non-Skeletonized) Internal Mammary Arteries: The Role of Thoracic Wall Ischemia?</p>. Vascular Health and Risk Management. Volume 16. 553–559.
4.
Daniels, Stephen R., Sonia Caprio, Umesh Chaudhari, et al.. (2020). PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. Journal of clinical lipidology. 14(3). 322–330.e5.
5.
Roth, Eli M., John J.P. Kastelein, Christopher P. Cannon, et al.. (2020). Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. Journal of clinical lipidology. 14(5). 707–719.
6.
Hurbin, Fabrice, Qiang Lü, Marie T. Baccara‐Dinet, et al.. (2019). Pharmacokinetics and Pharmacodynamics of Alirocumab, and Effects on PCSK9 and Low-Density Lipoprotein Cholesterol, in Japanese and Non-Japanese Patients. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 50(3). 73–80.
7.
Robinson, Jennifer G., Michel Farnier, John J.P. Kastelein, et al.. (2019). Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. Journal of clinical lipidology. 13(6). 979–988.e10.
8.
Brunet, Aurélie, et al.. (2018). Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I. Clinical Pharmacokinetics. 58(1). 101–113.
9.
Djebli, Nassim, et al.. (2018). Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II. Clinical Pharmacokinetics. 58(1). 115–130.
10.
Djebli, Nassim, et al.. (2017). Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies. Clinical Pharmacokinetics. 56(10). 1155–1171.
11.
Lebrun, Delphine, Thierry Floch, Aurélie Brunet, et al.. (2017). Severe post-artesunate delayed onset anaemia responding to corticotherapy: a case report. Journal of Travel Medicine. 25(1).
12.
Roth, Eli M., Anne C. Goldberg, Alberico L. Catapano, et al.. (2016). IMPACT OF ANTI-DRUG ANTIBODIES TO ALIROCUMAB ON LDL-C LOWERING EFFICACY AND SAFETY. Journal of the American College of Cardiology. 67(13). 1863–1863.
13.
Robinson, J, Michel Farnier, John J.P. Kastelein, et al.. (2016). Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis. 252. e231–e231.
14.
Poitiers, Franck, Aurélie Brunet, A. Thomas DiCioccio, et al.. (2016). Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies. Journal of the American Heart Association. 5(6).
15.
Poitiers, Franck, et al.. (2014). RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS. Journal of the American College of Cardiology. 63(12). A1375–A1375.
16.
Lunven, Catherine, et al.. (2014). A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects. Cardiovascular Therapeutics. 32(6). 297–301.
17.
Brunet, Aurélie, et al.. (2014). Separating the isomers—Efficient synthesis of the N-hydroxysuccinimide esters of 5 and 6-carboxyfluorescein diacetate and 5 and 6-carboxyrhodamine B. Bioorganic & Medicinal Chemistry Letters. 24(14). 3186–3188.
18.
Farnier, Michel, John J.P. Kastelein, Eli M. Roth, et al.. (2014). Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks. Atherosclerosis. 235(2). e34–e35.
19.
Stevenson, Louise, Adriana Tavares, Aurélie Brunet, et al.. (2009). New iodinated quinoline-2-carboxamides for SPECT imaging of the translocator protein. Bioorganic & Medicinal Chemistry Letters. 20(3). 954–957.
20.
Hoen, Bruno, B Aymard, A. Gérard, et al.. (1990). Sulfamethoxazole‐trimethoprim (SMZ‐TMP) as an effective therapy for Wegener's granulomatosis (WG) ‐ three more cases. Apmis. 98(S19). 65–65.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jennie Chang Breakdown of academic impact, for papers by Bas Peters Breakdown of academic impact, for papers by Julius L. Katzmann Breakdown of academic impact, for papers by Donald Moshen Tanyanyiwa Breakdown of academic impact, for papers by Sanae Kourimate Breakdown of academic impact, for papers by Francine Petrides Breakdown of academic impact, for papers by Kévin Chemello Breakdown of academic impact, for papers by Joseph Rubino Breakdown of academic impact, for papers by Ian Mongrain Breakdown of academic impact, for papers by Jared Spitz